Advagene Biopharma Co. Ltd.
Advagene Biopharma Co., Ltd. engages in the research and development of vaccine technology and related products in Taiwan. It engages in the development of nasal spray influenza vaccine; respiratory allergy treatment vaccine, including rhinitis and asthma; COVID-19 immunotherapy; and other vaccines. The company was founded in 2006 and is based in Taipei, Taiwan.
Advagene Biopharma Co. Ltd. (6709) - Net Assets
Latest net assets as of June 2025: NT$187.46 Million TWD
Based on the latest financial reports, Advagene Biopharma Co. Ltd. (6709) has net assets worth NT$187.46 Million TWD as of June 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (NT$197.26 Million) and total liabilities (NT$9.80 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | NT$187.46 Million |
| % of Total Assets | 95.03% |
| Annual Growth Rate | 0.45% |
| 5-Year Change | -26.32% |
| 10-Year Change | N/A |
| Growth Volatility | 37.71 |
Advagene Biopharma Co. Ltd. - Net Assets Trend (2017–2024)
This chart illustrates how Advagene Biopharma Co. Ltd.'s net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Advagene Biopharma Co. Ltd. (2017–2024)
The table below shows the annual net assets of Advagene Biopharma Co. Ltd. from 2017 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | NT$220.54 Million | +57.57% |
| 2023-12-31 | NT$139.96 Million | +6.22% |
| 2022-12-31 | NT$131.76 Million | -47.20% |
| 2021-12-31 | NT$249.57 Million | -16.62% |
| 2020-12-31 | NT$299.32 Million | +10.30% |
| 2019-12-31 | NT$271.37 Million | -21.77% |
| 2018-12-31 | NT$346.89 Million | +62.31% |
| 2017-12-31 | NT$213.72 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Advagene Biopharma Co. Ltd.'s total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 21278700000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | NT$683.80 Million | 310.06% |
| Total Equity | NT$220.54 Million | 100.00% |
Advagene Biopharma Co. Ltd. Competitors by Market Cap
The table below lists competitors of Advagene Biopharma Co. Ltd. ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
ESS Tech Inc
NYSE:GWH
|
$28.28 Million |
|
Budapesti Ingatlan Hasznositasi es Fejlesztesi Nyrt.
BUD:BIF
|
$28.29 Million |
|
Joong Ang Enervis Co. Ltd
KQ:000440
|
$28.29 Million |
|
Experience Co Ltd
AU:EXP
|
$28.29 Million |
|
Live Verdure Ltd
AU:LV1
|
$28.27 Million |
|
Gowing Bros Ltd
AU:GOW
|
$28.27 Million |
|
Molinos Juan Semino SA
BA:SEMI
|
$28.26 Million |
|
LTR Pharma Ltd
AU:LTP
|
$28.26 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Advagene Biopharma Co. Ltd.'s equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 139,962,000 to 220,541,000, a change of 80,579,000 (57.6%).
- Net loss of 69,421,000 reduced equity.
- New share issuances of 150,000,000 increased equity.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | NT$-69.42 Million | -31.48% |
| Share Issuances | NT$150.00 Million | +68.01% |
| Total Change | NT$- | 57.57% |
Book Value vs Market Value Analysis
This analysis compares Advagene Biopharma Co. Ltd.'s book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 8.33x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has increased from 6.43x to 8.33x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2017-12-31 | NT$4.81 | NT$30.95 | x |
| 2018-12-31 | NT$7.81 | NT$30.95 | x |
| 2019-12-31 | NT$6.08 | NT$30.95 | x |
| 2020-12-31 | NT$6.69 | NT$30.95 | x |
| 2021-12-31 | NT$5.07 | NT$30.95 | x |
| 2022-12-31 | NT$2.67 | NT$30.95 | x |
| 2023-12-31 | NT$2.78 | NT$30.95 | x |
| 2024-12-31 | NT$3.71 | NT$30.95 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Advagene Biopharma Co. Ltd. utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -31.48%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 1.05x
- Recent ROE (-31.48%) is above the historical average (-47.27%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2017 | -64.63% | 0.00% | 0.00x | 1.06x | NT$-159.50 Million |
| 2018 | -32.09% | 0.00% | 0.00x | 1.03x | NT$-146.01 Million |
| 2019 | -33.76% | 0.00% | 0.00x | 1.03x | NT$-118.75 Million |
| 2020 | -23.44% | 0.00% | 0.00x | 1.06x | NT$-100.09 Million |
| 2021 | -37.14% | 0.00% | 0.00x | 1.04x | NT$-117.64 Million |
| 2022 | -89.84% | 0.00% | 0.00x | 1.07x | NT$-131.55 Million |
| 2023 | -65.81% | 0.00% | 0.00x | 1.06x | NT$-106.11 Million |
| 2024 | -31.48% | 0.00% | 0.00x | 1.05x | NT$-91.48 Million |
Industry Comparison
This section compares Advagene Biopharma Co. Ltd.'s net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $1,581,964,900
- Average return on equity (ROE) among peers: 12.25%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Advagene Biopharma Co. Ltd. (6709) | NT$187.46 Million | -64.63% | 0.05x | $28.27 Million |
| Synbio Tech Inc. (1295) | $758.45 Million | 17.38% | 0.83x | $20.21K |
| Apex Biotechnology Corp (1733) | $712.76 Million | 14.13% | 0.13x | $64.53 Million |
| Sinphar Pharmaceutical Co Ltd (1734) | $3.78 Billion | 0.44% | 0.64x | $128.24 Million |
| Panion & BF Biotech Inc (1760) | $1.35 Billion | 11.79% | 0.36x | $120.05 Million |
| Chunghwa Chemical Synthesis & Biotech Co Ltd (1762) | $1.19 Billion | 20.52% | 0.94x | $40.94 Million |
| SYN-Tech Chem & Pharm Co Ltd (1777) | $2.59 Billion | 10.10% | 0.14x | $45.00 Million |
| Level Biotechnology (3118) | $549.47 Million | 11.45% | 0.50x | $22.42 Million |
| GenMont Biotech Inc (3164) | $1.48 Billion | 4.11% | 0.09x | $30.67 Million |
| Medigen Biotechnology (3176) | $2.69 Billion | -9.52% | 0.80x | $90.59 Million |
| Sagittarius Life Science (3205) | $714.71 Million | 42.07% | 0.58x | $56.62 Million |